Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Defining the Risk of Ventricular Tachycardia in Genetic Forms of Early-onset Atrial Fibrillation

Defining the Risk of Ventricular Tachycardia in Genetic Forms of Early-onset Atrial

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

To use programmed ventricular stimulation at the time of AF ablation to define the prevalence and mechanism of inducible ventricular tachycardia (VT); pace-mapping to define the site of origin of ventricular arrhythmias; and voltage mapping to define low voltage scar substrate in the basal LV in patients with pathogenic TTN variants compared to genotype-negative controls.

Who May Be Eligible (Plain English)

Who May Qualify: 1. Adults aged 18 and older 2. Diagnosed with AF before age 60 3. Scheduled for catheter-based AF ablation (de-novo or repeat) 4. Able to provide written, willing to sign a consent form 5. P/LP variant in TTN or other CM gene (cases) or identified as a genotype-negative control. Who Should NOT Join This Trial: 1. Diagnosed with a genetic CM or arrhythmia syndrome prior to AF 2. VUS in 'possibly pathogenic' subgroup (control group only) 3. Pacemaker or ICD 4. Previous PVC or VT ablation 5. LVEF \<20% 6. Prosthetic mitral or aortic valve 7. Contraindication to heparin 8. Prior myocardial infarction. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: 1. Adults aged 18 and older 2. Diagnosed with AF before age 60 3. Scheduled for catheter-based AF ablation (de-novo or repeat) 4. Able to provide written, informed consent 5. P/LP variant in TTN or other CM gene (cases) or identified as a genotype-negative control. Exclusion Criteria: 1. Diagnosed with a genetic CM or arrhythmia syndrome prior to AF 2. VUS in 'possibly pathogenic' subgroup (control group only) 3. Pacemaker or ICD 4. Previous PVC or VT ablation 5. LVEF \<20% 6. Prosthetic mitral or aortic valve 7. Contraindication to heparin 8. Prior myocardial infarction.

Treatments Being Tested

DIAGNOSTIC_TEST

EP Study

To use programmed ventricular stimulation at the time of AF ablation to define the prevalence and mechanism of inducible ventricular tachycardia (VT); pace-mapping to define the site of origin of ventricular arrhythmias; and voltage mapping to define low voltage scar substrate in the basal LV in patients with pathogenic TTN variants compared to genotype-negative controls.

Locations (1)

Vanderbilt University Medical Center
Nashville, Tennessee, United States